US5741817A - Use of low molecular weight amino acids in ophthalmic compositions - Google Patents

Use of low molecular weight amino acids in ophthalmic compositions Download PDF

Info

Publication number
US5741817A
US5741817A US08/575,740 US57574095A US5741817A US 5741817 A US5741817 A US 5741817A US 57574095 A US57574095 A US 57574095A US 5741817 A US5741817 A US 5741817A
Authority
US
United States
Prior art keywords
molecular weight
composition
low molecular
compositions
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/575,740
Inventor
Masood Chowhan
Bahram Asgharian
Paul Stach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Chowhan; Masood
Asgharian; Bahram
Stach; Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chowhan; Masood, Asgharian; Bahram, Stach; Paul filed Critical Chowhan; Masood
Priority to US08/575,740 priority Critical patent/US5741817A/en
Application granted granted Critical
Publication of US5741817A publication Critical patent/US5741817A/en
Assigned to ALCON MANUFACTURING, LTD. reassignment ALCON MANUFACTURING, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALCON LABORATORIES, INC.
Assigned to ALCON RESEARCH, LTD. reassignment ALCON RESEARCH, LTD. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ALCON MANUFACTURING, LTD.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids

Definitions

  • the present invention relates to the field of ophthalmology. More specifically, the invention relates to the use of glycine and other low molecular weight amino acids in products for treating contact lenses, as well as other ophthalmic products.
  • the amino acids described herein may serve several useful purposes in such compositions, but have been found to be particularly useful in enhancing the activity of antimicrobial preservatives.
  • Ethylenediaminetetraacetic acid and the monosodium, disodium and trisodium salts thereof have been widely used for many years in ophthalmic products, particularly products for treating contact lenses. It has been utilized in such products for various purposes, but particularly for its supplemental antimicrobial activity and as a chelating agent.
  • EDTA Ethylenediaminetetraacetic acid and the monosodium, disodium and trisodium salts thereof
  • compositions for treating contact lenses such as chlorine, iodine and other oxidizing agents.
  • the present invention is based on a new use of glycine and other low molecular weight amino acids.
  • the present inventors have found that such amino acids enhance the activity of antimicrobial preservatives, and are also useful as chelating agents.
  • the low molecular weight amino acids can also serve as buffers and tonicity agents. Based on these properties, glycine and the other amino acids described herein can be utilized in various types of ophthalmic compositions, particularly compositions for treating contact lenses, such as disinfectants, cleaners, comfort drops and rewetting drops, instead of EDTA.
  • the low molecular weight amino acids are particularly useful in preserved saline solutions which are utilized for rinsing and storing contact lenses.
  • the low molecular weight amino acids which may be utilized in the present invention have a molecular weight in the range of from about 75 to about 250.
  • the following compounds are representative of the low molecular weight amino acids which may be utilized in the present invention:
  • Amino acids which include alpha (a) carboxylic acid groups are preferred.
  • the amount of amino acid utilized will depend on the molecular weight of the amino acid(s) selected. In general, one or more of the above-described amino acids will be utilized in a concentration of from about 0.01 to about 7.5 percent by weight/volume (“w/v%").
  • the preferred amino acid for use in the present invention is glycine.
  • Glycine is a relatively simple, low molecular weight amino acid. It is also known as "aminoacetic acid".
  • the amount of glycine utilized in the compositions of the present invention will vary depending on the type of composition in which it is contained, and the function of glycine in the composition. In general, compositions which contain glycine for purposes of enhancing the antimicrobial activity of the compositions will contain glycine in an amount of from about 0.01 to about 2.5 w/v%., preferably from about 0.1 to about 1.0 w/v%. Similar amounts of glycine will be utilized to perform the other functions mentioned above.
  • low molecular weight amino acids may be combined with various ingredients conventionally utilized in ophthalmic products, particularly products for treating contact lenses. More specifically, these compounds may be utilized to enhance the antimicrobial activity of an ophthalmic composition, so as to preserve the composition against microbial contamination. Additionally, such compounds contribute to the tonicity, chelating and buffering properties of the composition.
  • the low molecular weight amino acids described herein may be included in various types of ophthalmic compositions to enhance antimicrobial activity, or for the other purposes mentioned above.
  • the types of compositions include: ophthalmic pharmaceutical compositions, such as topical compositions used in the treatment of glaucoma, infections, allergies or inflammation; compositions for treating contact lenses, such as cleaning products and products for enhancing the ocular comfort of patients wearing contact lenses; and various other types of compositions, such as ocular lubricating products, artificial tears, astringents, and so on.
  • the compositions may be aqueous or nonaqueous, but will generally be aqueous.
  • compositions of the present invention may contain one or more antimicrobial agents to preserve the compositions from microbial contamination.
  • the compositions may contain the antimicrobial agent known as POLYQUAD®; the use of this agent as a preservative in ophthalmic compositions is described in U.S. Pat. No. 4,525,346 (Stark). The entire contents of the Stark 346 patent are hereby incorporated in the present specification by reference.
  • Additional examples of antimicrobial agents include chlorhexidine, alexidine, hexetidine, polyhexamethylene biquanide, benzalkonium chloride, benzododecinum bromide, and other antimicrobial agents utilized as antimicrobial perservatives in ophthalmic compositions.
  • the inclusion of one or more of the above-described low molecular weight amino acids in ophthalmic compositions containing such antimicrobial preservatives enhances the overall antimicrobial activity of the compositions.
  • compositions may also contain a wide variety of other ingredients, such as tonicity agents (e.g., sodium chloride or mannitol), surfactants (e.g., alkyl ethoxylates and polyoxyethylene/polyoxypropylene copolymers), viscosity adjusting agents (e.g., hydroxypropyl methyl cellulose and other cellulose derivatives) and buffering agents (e.g., borates, citrates, phosphates and carbonates).
  • tonicity agents e.g., sodium chloride or mannitol
  • surfactants e.g., alkyl ethoxylates and polyoxyethylene/polyoxypropylene copolymers
  • viscosity adjusting agents e.g., hydroxypropyl methyl cellulose and other cellulose derivatives
  • buffering agents e.g., borates, citrates, phosphates and carbonates.
  • borate/mannitol buffering system is preferred. The use
  • compositions of the present invention preferably do not contain EDTA.
  • compositions will be formulated so as to be compatible with the eye and/or contact lenses to be treated with the compositions.
  • the ophthalmic compositions intended for direct application to the eye will be formulated so as to have a pH and tonicity which are compatible with the eye. This will normally require a buffer to maintain the pH of the composition at or near physiologic pH (i.e., 7.4) and may require a tonicity agent to bring the osmolality of the composition to a level at or near 280-320 milliosmoles per kilogram (“mOsm/kg").
  • the formulation of compositions for disinfecting and/or cleaning contact lenses will involve similar considerations, as well as considerations relating to the physical effect of the compositions on contact lens materials and the potential for binding or absorption of the components of the composition by the lens.
  • composition represents an example of a saline solution which does not contain any conventional antimicrobial preservatives.
  • This composition may be prepared by sequentially adding the ingredients to a portion of the distilled water and stirring the solution until each of the ingredients has dissolved. When all of the ingredients have been dissolved, the solution is brought to final volume by the addition of the remainder of the water, and the pH is adjusted, if necessary.
  • the solution has an osmolality of 295 mOsm/kg. It has been tested and found to meet the United States Pharmacopeia (“USP") and United States Food and Drug Administration (“FDA”) requirements for preservative effectiveness; those requirements are referred to below by means of the term "PET", which is an abbreviation for "preservative effectiveness test”.
  • USP United States Pharmacopeia
  • FDA United States Food and Drug Administration
  • PET is an abbreviation for "preservative effectiveness test”.
  • the above-described composition is referred to below as "Formulation A”.
  • the antimicrobial efficacy of Formulation A was evaluated. More specifically, the antimicrobial activity this saline solution was evaluated by inoculating 20 milliliters ("ml") of the solution with 0.1 ml of a microbial suspension. The final concentration was approximately 106 colony forming units per ml. At each time pull, the number of survivors was determined by taking a 1 ml aliquot of the test sample, serially diluting in 9 ml of saline at selected time intervals and preparing pour plates of SCDA. The bacteria and yeast plates were incubated at 30° C. to 35° C. for two to three days. The mold plates were incubated at 20° to 25° C. for five days. The results are presented in Table 1 below.
  • Formulation B represents an example of a saline solution containing a relatively high concentration of glycine in a borate buffer.
  • This solution was prepared by means of a procedure similar to the procedure described in Example 1 above.
  • the pH of the solution was 7.6 and the osmolality was 295 mOsm/kg.
  • the antimicrobial activity of Formulation B was evaluated against a gram negative and a gram positive bacteria by means of the procedures described in Example 2.
  • the solution showed a 2.2 log reduction against S. aureus and a 3.8 log reduction against P. aeruginosa at 7 days.
  • compositions were tested to determine if EDTA could simply be eliminated from saline solutions; the compositions were prepared by means of procedures similar to the procedure described in Example 1 above:
  • Formulation C has a pH of 7.7 and osmolality of 299 mOsm/kg
  • Formulation D has a pH of 7.7 and osmolality of 294 mOsm/kg
  • Formulation E has a pH of 7.3 and osmolality of 305 mOsm/kg.
  • composition represents an example of the preserved saline solutions of the present invention, wherein a low molecular weight amino acid is utilized to augment the activity of a conventional antimicrobial preservative.
  • This composition may be prepared by sequentially adding the listed ingredients to 90 ml of purified water and stirring until each ingredient has dissolved. The pH is adjusted to 7.4 and the volume is adjusted to 100 ml.
  • the low molecular weight amino i.e., glycine
  • the above composition is an example of a composition for lubricating contact lenses or increasing the comfort of contact lenses when worn by patients.
  • the composition is prepared in two parts and then recombined.
  • polyvinyl alcohol and hydroxyethyl cellulose are dispersed in 40 ml of purified water at a temperature of 50°-70° C., and then allowed to hydrate and cool to room temperature.
  • the solution is then Polish filtered using a 5-20 micrometer ("pm") membrane filter and autoclaved.
  • the remaining ingredients are dissolved in 50 ml of purified water. This solution is then sterile filtered using a 0.22 ⁇ m membrane filter into a sterile receiving container.
  • the first part and the second part are then combined aseptically and the pH of the resulting solution is adjusted to 7.4.
  • the volume of the solution is then brought to 100 ml with purified water.
  • the solution has an osmolality of 230-260 mOsm/kg.
  • a low molecular weight amino acid in this composition enhances the antimicrobial activity of the composition, and also eliminates the need for an additional tonicity agent, such as sodium chloride.
  • the above composition is an example of a multi-purpose solution for cleaning, disinfecting and storing contact lenses.
  • the composition was prepared by sequentially adding the ingredients to 90 ml of purified water and stirring until each ingredient was dissolved.
  • the pH of the resulting solution was adjusted to 7.4, and the volume was adjusted to 100 ml with purified water.
  • the low molecular weight amino acid performs the same function in this composition as in the other compositions described above.

Abstract

The use of glycine and other low molecular weight amino acids in ophthalmic compositions (e.g., preserved saline solutions) is described. These compounds have been found to enhance the efficacy of antimicrobial preservatives. The compounds also act as chelating agents, buffers and tonicity agents.

Description

This is a continuation of application Ser. No. 08/279,324, filed Jul. 22, 1994, abandoned.
BACKGROUND OF THE INVENTION
The present invention relates to the field of ophthalmology. More specifically, the invention relates to the use of glycine and other low molecular weight amino acids in products for treating contact lenses, as well as other ophthalmic products. The amino acids described herein may serve several useful purposes in such compositions, but have been found to be particularly useful in enhancing the activity of antimicrobial preservatives.
Ethylenediaminetetraacetic acid and the monosodium, disodium and trisodium salts thereof (collectively referred to herein as "EDTA") have been widely used for many years in ophthalmic products, particularly products for treating contact lenses. It has been utilized in such products for various purposes, but particularly for its supplemental antimicrobial activity and as a chelating agent. The inclusion of EDTA in contact lens care products and other ophthalmic compositions enhances the antimicrobial efficacy of chemical preservatives contained in such compositions, particularly the efficacy of those preservatives against gram negative bacteria. However, some scientific studies have indicated that EDTA may damage corneal cells. See, e.g., Collin, et al., "The Effects of Na2EDTA on Keratocytes and Endothelium of the Isolated Guinea Pig Cornea", International Contact Lens Clinic, volume 9, number 5, September/October 1982. Further, it is incompatible with certain components of compositions for treating contact lenses, such as chlorine, iodine and other oxidizing agents.
In view of the foregoing circumstances, there is a need for a new agent which can perform essentially the same functions as EDTA, but which is more compatible with corneal cells and chemically compatible with oxidizing agents. The new use of glycine and other low molecular weight amino acids described herein is directed to satisfying this need.
SUMMARY OF THE INVENTION
The present invention is based on a new use of glycine and other low molecular weight amino acids. The present inventors have found that such amino acids enhance the activity of antimicrobial preservatives, and are also useful as chelating agents. The low molecular weight amino acids can also serve as buffers and tonicity agents. Based on these properties, glycine and the other amino acids described herein can be utilized in various types of ophthalmic compositions, particularly compositions for treating contact lenses, such as disinfectants, cleaners, comfort drops and rewetting drops, instead of EDTA. The low molecular weight amino acids are particularly useful in preserved saline solutions which are utilized for rinsing and storing contact lenses.
DESCRIPTION OF PREFERRED EMBODIMENTS
The low molecular weight amino acids which may be utilized in the present invention have a molecular weight in the range of from about 75 to about 250. The following compounds are representative of the low molecular weight amino acids which may be utilized in the present invention:
______________________________________                                    
L-Alanine          β-Alanine                                         
α-Aminoadipic Acid                                                  
                   α-Aminobutyric Acid                              
γ-Aminobutyric Acid                                                 
                   α-Aminoisobutyric Acid                           
Arginine           Asparagine                                             
Aspartic Acid      Citrulline                                             
Creatine           Glutamic Acid                                          
Glycine            Histidine                                              
Cystine            Leucine                                                
Lysine             Norleucine                                             
Ornithine          Phenylalanine                                          
Phophoserine       Sarcosine                                              
Threonine          Valine                                                 
______________________________________
Amino acids which include alpha (a) carboxylic acid groups are preferred.
The amount of amino acid utilized will depend on the molecular weight of the amino acid(s) selected. In general, one or more of the above-described amino acids will be utilized in a concentration of from about 0.01 to about 7.5 percent by weight/volume ("w/v%").
The preferred amino acid for use in the present invention is glycine. Glycine is a relatively simple, low molecular weight amino acid. It is also known as "aminoacetic acid". The amount of glycine utilized in the compositions of the present invention will vary depending on the type of composition in which it is contained, and the function of glycine in the composition. In general, compositions which contain glycine for purposes of enhancing the antimicrobial activity of the compositions will contain glycine in an amount of from about 0.01 to about 2.5 w/v%., preferably from about 0.1 to about 1.0 w/v%. Similar amounts of glycine will be utilized to perform the other functions mentioned above.
The above-described low molecular weight amino acids may be combined with various ingredients conventionally utilized in ophthalmic products, particularly products for treating contact lenses. More specifically, these compounds may be utilized to enhance the antimicrobial activity of an ophthalmic composition, so as to preserve the composition against microbial contamination. Additionally, such compounds contribute to the tonicity, chelating and buffering properties of the composition.
The low molecular weight amino acids described herein may be included in various types of ophthalmic compositions to enhance antimicrobial activity, or for the other purposes mentioned above. The types of compositions include: ophthalmic pharmaceutical compositions, such as topical compositions used in the treatment of glaucoma, infections, allergies or inflammation; compositions for treating contact lenses, such as cleaning products and products for enhancing the ocular comfort of patients wearing contact lenses; and various other types of compositions, such as ocular lubricating products, artificial tears, astringents, and so on. The compositions may be aqueous or nonaqueous, but will generally be aqueous.
The compositions of the present invention may contain one or more antimicrobial agents to preserve the compositions from microbial contamination. For example, the compositions may contain the antimicrobial agent known as POLYQUAD®; the use of this agent as a preservative in ophthalmic compositions is described in U.S. Pat. No. 4,525,346 (Stark). The entire contents of the Stark 346 patent are hereby incorporated in the present specification by reference. Additional examples of antimicrobial agents include chlorhexidine, alexidine, hexetidine, polyhexamethylene biquanide, benzalkonium chloride, benzododecinum bromide, and other antimicrobial agents utilized as antimicrobial perservatives in ophthalmic compositions. The inclusion of one or more of the above-described low molecular weight amino acids in ophthalmic compositions containing such antimicrobial preservatives enhances the overall antimicrobial activity of the compositions.
As will be appreciated by those skilled in the art, the compositions may also contain a wide variety of other ingredients, such as tonicity agents (e.g., sodium chloride or mannitol), surfactants (e.g., alkyl ethoxylates and polyoxyethylene/polyoxypropylene copolymers), viscosity adjusting agents (e.g., hydroxypropyl methyl cellulose and other cellulose derivatives) and buffering agents (e.g., borates, citrates, phosphates and carbonates). The use of a borate/mannitol buffering system is preferred. The use of such systems is described in copending, commonly assigned U.S. patent application Ser. No. 08/198,427 filed Feb. 21, 1994, and in corresponding PCT International Application Number PCT/US93/04226 (International Publication Number WO 93/21903); the entire contents of the foregoing applications are hereby incorporated in the present specification by reference. The present invention is not limited with respect to the types of ophthalmic compositions in which glycine and the other low molecular weight amino acids described above are utilized. However, the compositions of the present invention preferably do not contain EDTA.
All of the above-described compositions will be formulated so as to be compatible with the eye and/or contact lenses to be treated with the compositions. As will be appreciated by those skilled in the art, the ophthalmic compositions intended for direct application to the eye will be formulated so as to have a pH and tonicity which are compatible with the eye. This will normally require a buffer to maintain the pH of the composition at or near physiologic pH (i.e., 7.4) and may require a tonicity agent to bring the osmolality of the composition to a level at or near 280-320 milliosmoles per kilogram ("mOsm/kg"). The formulation of compositions for disinfecting and/or cleaning contact lenses will involve similar considerations, as well as considerations relating to the physical effect of the compositions on contact lens materials and the potential for binding or absorption of the components of the composition by the lens.
The following examples are presented to further illustrate the present invention.
EXAMPLE 1 
______________________________________                                    
Ingredient    Concentration (w/v %)                                       
______________________________________                                    
Boric Acid    1.0                                                         
Mannitol      1.5                                                         
Glycine       0.75                                                        
Pationic 138C 0.01                                                        
KOH/HCl       pH 7.4                                                      
Purified Water                                                            
              q.s.                                                        
______________________________________
The above composition represents an example of a saline solution which does not contain any conventional antimicrobial preservatives. This composition may be prepared by sequentially adding the ingredients to a portion of the distilled water and stirring the solution until each of the ingredients has dissolved. When all of the ingredients have been dissolved, the solution is brought to final volume by the addition of the remainder of the water, and the pH is adjusted, if necessary. The solution has an osmolality of 295 mOsm/kg. It has been tested and found to meet the United States Pharmacopeia ("USP") and United States Food and Drug Administration ("FDA") requirements for preservative effectiveness; those requirements are referred to below by means of the term "PET", which is an abbreviation for "preservative effectiveness test". The above-described composition is referred to below as "Formulation A".
EXAMPLE 2
The antimicrobial efficacy of Formulation A was evaluated. More specifically, the antimicrobial activity this saline solution was evaluated by inoculating 20 milliliters ("ml") of the solution with 0.1 ml of a microbial suspension. The final concentration was approximately 106 colony forming units per ml. At each time pull, the number of survivors was determined by taking a 1 ml aliquot of the test sample, serially diluting in 9 ml of saline at selected time intervals and preparing pour plates of SCDA. The bacteria and yeast plates were incubated at 30° C. to 35° C. for two to three days. The mold plates were incubated at 20° to 25° C. for five days. The results are presented in Table 1 below.
              TABLE 1                                                     
______________________________________                                    
Antimicrobial Activity of Formulation A                                   
Against PET Microorganisms                                                
Organism        Time    Log Reduction                                     
______________________________________                                    
A. niger         7 Days 2.5                                               
                14 Days 1.5                                               
                21 Days 1.5                                               
                28 Days 1.4                                               
                35 Days 1.6                                               
C. albicans      7 days 3.7                                               
                14 Days 4.7                                               
                21 Days 3.2                                               
                28 Days 4.5                                               
P. aeruginosa    7 Days 3.5                                               
                14 Days 5.2                                               
                21 Days 3.1                                               
                28 Days 3.8                                               
E. coli          7 Days 3.5                                               
                14 Days 4.9                                               
                21 Days 3.3                                               
                28 Days 3.9                                               
S. aureus        7 Days 5.0                                               
                14 Days 5.0                                               
                21 Days 4.9                                               
                28 Days 4.6                                               
______________________________________
EXAMPLE 3 
______________________________________                                    
Ingredient    Concentration (w/v %)                                       
______________________________________                                    
Boric Acid    0.442                                                       
Sodium Borate 0.0875                                                      
Glycine       1.61                                                        
Pationic 138C 0.01                                                        
Purified Water                                                            
              q.s.                                                        
______________________________________
The above composition, which is referred to herein as "Formulation B", represents an example of a saline solution containing a relatively high concentration of glycine in a borate buffer. This solution was prepared by means of a procedure similar to the procedure described in Example 1 above. The pH of the solution was 7.6 and the osmolality was 295 mOsm/kg. The antimicrobial activity of Formulation B was evaluated against a gram negative and a gram positive bacteria by means of the procedures described in Example 2. The solution showed a 2.2 log reduction against S. aureus and a 3.8 log reduction against P. aeruginosa at 7 days.
EXAMPLE 4
The following compositions were tested to determine if EDTA could simply be eliminated from saline solutions; the compositions were prepared by means of procedures similar to the procedure described in Example 1 above:
______________________________________                                    
        Concentration (w/v %)                                             
Ingredient                                                                
          Formulation C                                                   
                      Formulation D                                       
                                 Formulation E                            
______________________________________                                    
Boric Acid                                                                
          0.442       0.442      0.442                                    
Sodium Borate                                                             
          0.0875      0.0875     0.0874                                   
Sodium Chloride                                                           
          0.675       0.675      0.675                                    
Pationic 138C                                                             
          --          0.01       0.01                                     
Disodium Edetate                                                          
          --          --         0.1                                      
Purified Water                                                            
          q.s         q.s.       q.s.                                     
______________________________________
Formulation C has a pH of 7.7 and osmolality of 299 mOsm/kg, Formulation D has a pH of 7.7 and osmolality of 294 mOsm/kg, and Formulation E has a pH of 7.3 and osmolality of 305 mOsm/kg. The compositions were tested for antimicrobial activity by means of the procedures described in Example 2. The results, expressed as the number of log reductions after 7 days, are listed below:
______________________________________                                    
Antimicrobial Activity (i.e., Log Reduction at Day 7)                     
Against PET Microorganisms                                                
       Formulation C                                                      
                  Formulation D                                           
                             Formulation E                                
______________________________________                                    
A. niger 1.8          1.9        1.0                                      
P. aeruginosa                                                             
         0.0          0.4        4.1                                      
S. aureus                                                                 
         1.6          4.1        5.0                                      
______________________________________
Both Formulation C and Formulation D failed USP and FDA requirements for preservative effectiveness, while Formulation E met those requirements. These results clearly demonstrate that EDTA cannot simply eliminated. This is particularly true relative to Pseudomonas aeruginosa. However, the results presented in Examples 2 and 3 demonstrate that EDTA can be replaced by low molecular weight amino acids, such as glycine.
EXAMPLE 5 
______________________________________                                    
Ingredient    Concentration (w/v %)                                       
______________________________________                                    
Boric acid    0.35                                                        
Sodium borate 0.11                                                        
Mannitol      1.5                                                         
Glycine       0.75                                                        
Polyquad      0.001                                                       
Purified water                                                            
              q.s.                                                        
______________________________________
The above composition represents an example of the preserved saline solutions of the present invention, wherein a low molecular weight amino acid is utilized to augment the activity of a conventional antimicrobial preservative. This composition may be prepared by sequentially adding the listed ingredients to 90 ml of purified water and stirring until each ingredient has dissolved. The pH is adjusted to 7.4 and the volume is adjusted to 100 ml. The low molecular weight amino (i.e., glycine) contributes to the antimicrobial properties of the solution, as well as to the tonicity and chelating properties of the solution.
EXAMPLE 6 
______________________________________                                    
Ingredient      Concentration (w/v %)                                     
______________________________________                                    
Polyvinyl alcohol                                                         
                0.75                                                      
Hydroxyethyl cellulose                                                    
                0.28                                                      
Boric acid      0.35                                                      
Sodium borate   0.11                                                      
Mannitol        2.0                                                       
Glycine         0.5                                                       
Polyquad ™   0.001                                                     
Purified water  q.s.                                                      
______________________________________
The above composition is an example of a composition for lubricating contact lenses or increasing the comfort of contact lenses when worn by patients. The composition is prepared in two parts and then recombined. In order to prepare the first part, polyvinyl alcohol and hydroxyethyl cellulose are dispersed in 40 ml of purified water at a temperature of 50°-70° C., and then allowed to hydrate and cool to room temperature. The solution is then Polish filtered using a 5-20 micrometer ("pm") membrane filter and autoclaved. In order to prepare the second part, the remaining ingredients are dissolved in 50 ml of purified water. This solution is then sterile filtered using a 0.22 μm membrane filter into a sterile receiving container. The first part and the second part are then combined aseptically and the pH of the resulting solution is adjusted to 7.4. The volume of the solution is then brought to 100 ml with purified water. The solution has an osmolality of 230-260 mOsm/kg.
The use of a low molecular weight amino acid in this composition enhances the antimicrobial activity of the composition, and also eliminates the need for an additional tonicity agent, such as sodium chloride.
EXAMPLE 7 
______________________________________                                    
Ingredient     Concentration (w/v %)                                      
______________________________________                                    
Polaxamine     0.25                                                       
Boric acid     0.5                                                        
Mannitol       1.5                                                        
Sodium chloride                                                           
               0.15                                                       
Glycine        0.25                                                       
Polyhexamethylene                                                         
               0.0005                                                     
biquanide                                                                 
Purified water q.s.                                                       
______________________________________
The above composition is an example of a multi-purpose solution for cleaning, disinfecting and storing contact lenses. The composition was prepared by sequentially adding the ingredients to 90 ml of purified water and stirring until each ingredient was dissolved. The pH of the resulting solution was adjusted to 7.4, and the volume was adjusted to 100 ml with purified water. The low molecular weight amino acid performs the same function in this composition as in the other compositions described above.

Claims (7)

What is claimed is:
1. A method of enhancing the antimicrobial activity of an ophthalmic composition which comprises adding to the composition an effective amount of a low molecular weight amino acid, said amino acid including an alpha carboxylic acid group and having a molecular weight of 75 to 250, wherein the ophthalmic composition does not contain EDTA.
2. A method according to claim 1, wherein the amino acid comprises glycine.
3. A method according to claim 1, wherein the composition is a contact lens disinfecting solution.
4. A method according to claim 2, wherein the composition is a contact lens disinfecting solution.
5. A method according to claim 1, wherein the composition is a saline solution adapted for rinsing and storing contact lenses.
6. A method according to claim 5, wherein the low molecular weight amino acid comprises glycine in an amount effect to preserve the saline solution from microbial contamination.
7. A method according to claim 6, wherein the saline solution has the following formula:
______________________________________                                    
Ingredient    Concentration (w/v %)                                       
______________________________________                                    
Boric Acid    1.0                                                         
Mannitol      1.5                                                         
Glycine       0.75                                                        
Pationic 138C 0.01                                                        
KOH/HCl       pH 7.4                                                      
Purified Water                                                            
              q.s..                                                       
______________________________________
US08/575,740 1994-07-22 1995-12-18 Use of low molecular weight amino acids in ophthalmic compositions Expired - Lifetime US5741817A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/575,740 US5741817A (en) 1994-07-22 1995-12-18 Use of low molecular weight amino acids in ophthalmic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932494A 1994-07-22 1994-07-22
US08/575,740 US5741817A (en) 1994-07-22 1995-12-18 Use of low molecular weight amino acids in ophthalmic compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US27932494A Continuation 1994-07-22 1994-07-22

Publications (1)

Publication Number Publication Date
US5741817A true US5741817A (en) 1998-04-21

Family

ID=23068484

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/575,740 Expired - Lifetime US5741817A (en) 1994-07-22 1995-12-18 Use of low molecular weight amino acids in ophthalmic compositions

Country Status (3)

Country Link
US (1) US5741817A (en)
AU (1) AU3070395A (en)
WO (1) WO1996003158A1 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6180093B1 (en) * 1996-09-20 2001-01-30 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US6211238B1 (en) 1998-10-27 2001-04-03 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
US6284749B1 (en) 1998-10-27 2001-09-04 Alcon Manufacturing, Ltd. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6444710B1 (en) 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US20030153622A1 (en) * 2001-09-17 2003-08-14 Menicon Co., Ltd. Ophthalmic solution and contact lens solution
US6617291B1 (en) 2001-11-08 2003-09-09 Francis X. Smith Ophthalmic and contact lens solutions
US6620797B2 (en) 2000-12-21 2003-09-16 Alcon, Inc. Artificial tear composition containing a combination of three demulcents
US6624203B1 (en) 2001-11-08 2003-09-23 Francis X. Smith Nucleic acid bases used in ophthalmic solutions
US20030190258A1 (en) * 2000-11-04 2003-10-09 Smith Francis X. Ophthalmic and contact lens solutions using low molecular weight amines
US20040241206A1 (en) * 2001-12-21 2004-12-02 Ketelson Howard Allen Use of nanoparticles as carriers for biocides in ophthalmic compositions
US20050002970A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions
US20050003014A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20050042198A1 (en) * 1999-11-04 2005-02-24 Smith Francis X. Ophthalmic and contact lens wetting solutions
US20050124702A1 (en) * 2003-12-09 2005-06-09 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
US20050154065A1 (en) * 2003-12-09 2005-07-14 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20060078626A1 (en) * 2000-11-08 2006-04-13 Bioconcept Laboratories Opthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US20060142169A1 (en) * 2000-11-08 2006-06-29 Bioconcept Laboratories Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20060141059A1 (en) * 2004-12-27 2006-06-29 Alcon, Inc. Self-preserved ophthalmic pharmaceutical compositions containing tobramycin
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
WO2007048523A1 (en) * 2005-10-26 2007-05-03 Solartium Enterprises Limited Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate
US20070098813A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions with a peroxide source and a preservative
US20070098818A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
US20080075790A1 (en) * 2006-09-21 2008-03-27 Alcon Manufacturing, Ltd. Self preserved aqueous pharmaceutical compositions
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US20080096966A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions containing diglycine
US20080093247A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080167246A1 (en) * 2003-04-15 2008-07-10 Bioconcept Laboratories Ophthalmic and Contact Lens Solutions Containing Peptides as Preservative
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
US20090074879A1 (en) * 2005-08-11 2009-03-19 Gianluca Braguti Wound-Healing Composition
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
US20090234004A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Pharmaceutical compositions having desirable bioavailability
US20090247469A1 (en) * 2008-03-25 2009-10-01 Burke Susan E Ophthalmic compositions comprising a dipeptide
US20100021561A1 (en) * 2006-09-21 2010-01-28 Chowhan Masood A Self-preserved aqueous pharmaceutical compositions
US20100021562A1 (en) * 2006-09-28 2010-01-28 Chowhan Masood A Self preserved aqueous pharmaceutical compositions
US20100324031A1 (en) * 2009-06-19 2010-12-23 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
WO2011053569A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1190718T3 (en) * 1996-12-13 2006-09-25 Alcon Lab Inc Ophthalmic compositions comprising amino alcohols
KR100366676B1 (en) * 1996-12-13 2003-01-14 알콘 래보레이토리스, 인코퍼레이티드 Use of low molecular weight amino alcohols in ophthalmic compositions
WO2006138709A2 (en) 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
UY31057A1 (en) * 2007-05-01 2008-10-31 Alcon Res Ltd N-HALOGENATED AMINO ACID FORMULATIONS CONTAINING ALIFATIC ACID
TWI607768B (en) * 2017-03-31 2017-12-11 晶碩光學股份有限公司 Composition for contact lenses and method for caring contact lenses

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410442A (en) * 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US4504405A (en) * 1980-12-18 1985-03-12 Smith And Nephew Associated Companies P.L.C. Method of cleaning soft contact lenses
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4710313A (en) * 1985-06-26 1987-12-01 Lion Corporation Detergent composition for contact lenses
EP0297598A2 (en) * 1987-07-03 1989-01-04 Hoechst Aktiengesellschaft Spore inactivating agent and process for prolonging the shelf life of products and materials susceptible to putrefaction
US5011661A (en) * 1985-07-10 1991-04-30 Ciba-Geigy Corporation Contact lens care set
WO1993021903A1 (en) * 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
WO1995030414A1 (en) * 1994-05-06 1995-11-16 Smith Francis X An improved ocular care solution

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
EP0079185B1 (en) * 1981-11-06 1986-02-12 Smith and Nephew Associated Companies p.l.c. Cleaning solution

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504405A (en) * 1980-12-18 1985-03-12 Smith And Nephew Associated Companies P.L.C. Method of cleaning soft contact lenses
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4410442A (en) * 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US4710313A (en) * 1985-06-26 1987-12-01 Lion Corporation Detergent composition for contact lenses
US5011661A (en) * 1985-07-10 1991-04-30 Ciba-Geigy Corporation Contact lens care set
EP0297598A2 (en) * 1987-07-03 1989-01-04 Hoechst Aktiengesellschaft Spore inactivating agent and process for prolonging the shelf life of products and materials susceptible to putrefaction
AU1860488A (en) * 1987-07-03 1989-01-05 Hoechst Aktiengesellschaft Agent for inactivating spores and process for prolonging the storage life of products, substances or produce which can be spoiled by bacterial spore infestation
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
WO1993021903A1 (en) * 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
WO1995030414A1 (en) * 1994-05-06 1995-11-16 Smith Francis X An improved ocular care solution

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Collin, et al., "The Effects of Na2 EDTA on Keratocytes and Endothelium of the Isolated Guinea Pig Cornea", International Contact Lens Clinic, vol. 9, No. 5, pp. 281-287 (Sep./Oct. 1982).
Collin, et al., The Effects of Na 2 EDTA on Keratocytes and Endothelium of the Isolated Guinea Pig Cornea , International Contact Lens Clinic , vol. 9, No. 5, pp. 281 287 (Sep./Oct. 1982). *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180093B1 (en) * 1996-09-20 2001-01-30 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US6211238B1 (en) 1998-10-27 2001-04-03 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
US6284749B1 (en) 1998-10-27 2001-09-04 Alcon Manufacturing, Ltd. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6444710B1 (en) 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US20050042198A1 (en) * 1999-11-04 2005-02-24 Smith Francis X. Ophthalmic and contact lens wetting solutions
US8247461B2 (en) 1999-11-04 2012-08-21 Smith Francis X Ophthalmic and contact lens solution
US20100122918A1 (en) * 1999-11-04 2010-05-20 Smith Francis X Ophthalmic and contact lens solution
US8557868B2 (en) 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20030190258A1 (en) * 2000-11-04 2003-10-09 Smith Francis X. Ophthalmic and contact lens solutions using low molecular weight amines
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US10064410B2 (en) 2000-11-08 2018-09-04 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US20060142169A1 (en) * 2000-11-08 2006-06-29 Bioconcept Laboratories Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20060078626A1 (en) * 2000-11-08 2006-04-13 Bioconcept Laboratories Opthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US9492582B2 (en) 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US9492581B2 (en) 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
US20070098818A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US10595532B2 (en) 2000-11-08 2020-03-24 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US9585394B2 (en) 2000-11-08 2017-03-07 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20070098813A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions with a peroxide source and a preservative
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US6620797B2 (en) 2000-12-21 2003-09-16 Alcon, Inc. Artificial tear composition containing a combination of three demulcents
US20030153622A1 (en) * 2001-09-17 2003-08-14 Menicon Co., Ltd. Ophthalmic solution and contact lens solution
US6806243B2 (en) * 2001-09-17 2004-10-19 Menicon Co., Ltd. Ophthalmic solution and contact lens solution
US6617291B1 (en) 2001-11-08 2003-09-09 Francis X. Smith Ophthalmic and contact lens solutions
US6624203B1 (en) 2001-11-08 2003-09-23 Francis X. Smith Nucleic acid bases used in ophthalmic solutions
US8257745B2 (en) 2001-12-21 2012-09-04 Novartis Ag Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20040241206A1 (en) * 2001-12-21 2004-12-02 Ketelson Howard Allen Use of nanoparticles as carriers for biocides in ophthalmic compositions
US8097270B2 (en) 2001-12-21 2012-01-17 Novartis Ag Use of nanoparticles as carriers for biocides in ophthalmic compositions
US20050003014A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20050002970A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions
US20110212885A1 (en) * 2003-04-15 2011-09-01 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
US7939501B2 (en) 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
US20080167246A1 (en) * 2003-04-15 2008-07-10 Bioconcept Laboratories Ophthalmic and Contact Lens Solutions Containing Peptides as Preservative
US7871602B2 (en) 2003-12-09 2011-01-18 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20050124702A1 (en) * 2003-12-09 2005-06-09 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
US7445771B2 (en) 2003-12-09 2008-11-04 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20050154065A1 (en) * 2003-12-09 2005-07-14 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20090030085A1 (en) * 2003-12-09 2009-01-29 Alcon, Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
WO2005060953A1 (en) * 2003-12-09 2005-07-07 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
EP2062872A2 (en) 2003-12-09 2009-05-27 Alcon Inc. Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
US20080089953A1 (en) * 2004-12-27 2008-04-17 Alcon, Inc. Self-Preserved Ophthalmic Pharmaceutical Compositions Containing Tobramycin
US20060141059A1 (en) * 2004-12-27 2006-06-29 Alcon, Inc. Self-preserved ophthalmic pharmaceutical compositions containing tobramycin
US20090074879A1 (en) * 2005-08-11 2009-03-19 Gianluca Braguti Wound-Healing Composition
US20080249065A1 (en) * 2005-10-26 2008-10-09 Franco Conti Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate
WO2007048523A1 (en) * 2005-10-26 2007-05-03 Solartium Enterprises Limited Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
US20080075790A1 (en) * 2006-09-21 2008-03-27 Alcon Manufacturing, Ltd. Self preserved aqueous pharmaceutical compositions
US20100021561A1 (en) * 2006-09-21 2010-01-28 Chowhan Masood A Self-preserved aqueous pharmaceutical compositions
US8268299B2 (en) 2006-09-21 2012-09-18 Alcon Research, Ltd. Self preserved aqueous pharmaceutical compositions
US20110195132A1 (en) * 2006-09-21 2011-08-11 Alcon Research, Ltd. Self-Preserved Aqueous Pharmaceutical Compositions
US8323630B2 (en) 2006-09-21 2012-12-04 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
US20100021562A1 (en) * 2006-09-28 2010-01-28 Chowhan Masood A Self preserved aqueous pharmaceutical compositions
US8388941B2 (en) 2006-09-28 2013-03-05 Alcon Research, Ltd. Self preserved aqueous pharmaceutical compositions
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US20080096966A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions containing diglycine
US8138156B2 (en) 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
WO2008049043A2 (en) * 2006-10-18 2008-04-24 Bausch & Lomb Incorporated Ophthalmic compositions comprising diglycine
WO2008049043A3 (en) * 2006-10-18 2008-06-19 Bausch & Lomb Ophthalmic compositions comprising diglycine
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US20080093247A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
DE202009019087U1 (en) 2008-03-17 2016-05-20 Alcon Research, Ltd. Pharmaceutical compositions with desirable bioavailability
US8178582B2 (en) 2008-03-17 2012-05-15 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US20090234004A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Pharmaceutical compositions having desirable bioavailability
EP2599475A2 (en) 2008-03-17 2013-06-05 Alcon Research, Ltd. Pharmaceutical composition having desirable bioavailability
US20090234013A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Pharmaceutical compositions having desirable bioavailability
WO2009117316A2 (en) 2008-03-17 2009-09-24 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
DE202009019114U1 (en) 2008-03-17 2016-08-01 Alcon Research, Ltd. Pharmaceutical compositions with desirable bioavailability
EP2705836A1 (en) 2008-03-17 2014-03-12 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US8722735B2 (en) 2008-03-17 2014-05-13 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US8754123B2 (en) 2008-03-17 2014-06-17 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
EP3042646A1 (en) 2008-03-17 2016-07-13 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US9144561B2 (en) 2008-03-17 2015-09-29 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US8629099B2 (en) 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
WO2009120562A1 (en) * 2008-03-25 2009-10-01 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
US20090247469A1 (en) * 2008-03-25 2009-10-01 Burke Susan E Ophthalmic compositions comprising a dipeptide
US20100324031A1 (en) * 2009-06-19 2010-12-23 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
US9044484B2 (en) 2009-06-19 2015-06-02 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
US9421265B2 (en) 2009-06-19 2016-08-23 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
WO2011053569A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
US20110123622A1 (en) * 2009-10-26 2011-05-26 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine

Also Published As

Publication number Publication date
WO1996003158A1 (en) 1996-02-08
AU3070395A (en) 1996-02-22

Similar Documents

Publication Publication Date Title
US5741817A (en) Use of low molecular weight amino acids in ophthalmic compositions
US5756045A (en) Method and composition for disinfecting contact lenses
JP4276139B2 (en) Use of low molecular weight amino alcohols in ophthalmic compositions
EP0929292B1 (en) Method and composition for rewetting contact lenses and relieving eye dryness
EP0772669B1 (en) Saline solution for treating contact lenses
AU2003210699B2 (en) Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
EP2155271B1 (en) Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
AU2003210699A1 (en) Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
JP2005502392A (en) Composition containing vitamin surfactant and method of using the same
EP1190718A2 (en) Ophthalmic compositions comprising amino alcohols
IE920220A1 (en) Method and composition for disinfecting contact lenses

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ALCON MANUFACTURING, LTD., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON LABORATORIES, INC.;REEL/FRAME:011667/0559

Effective date: 20010322

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ALCON RESEARCH, LTD., TEXAS

Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729

Effective date: 20080101

Owner name: ALCON RESEARCH, LTD.,TEXAS

Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729

Effective date: 20080101

FPAY Fee payment

Year of fee payment: 12